Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Burns Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Burns Overview | 11 | 1 |
| Pipeline Products for Burns Comparative Analysis | 12 | 1 |
| Burns Therapeutics under Development by Companies | 13 | 2 |
| Burns Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Burns Pipeline Products Glance | 16 | 4 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Unknown Stage Products | 19 | 1 |
| Burns Products under Development by Companies | 20 | 2 |
| Burns Products under Investigation by Universities/Institutes | 22 | 1 |
| Burns Companies Involved in Therapeutics Development | 23 | 17 |
| Adocia | 23 | 1 |
| AlgiPharma AS | 24 | 1 |
| Amarantus Bioscience Holdings, Inc. | 25 | 1 |
| American Gene Technologies International Inc. | 26 | 1 |
| Biogenomics Limited | 27 | 1 |
| CytoTools AG | 28 | 1 |
| Destiny Pharma Limited | 29 | 1 |
| Lakewood-Amedex Inc | 30 | 1 |
| Madam Therapeutics B.V. | 31 | 1 |
| MediWound Ltd. | 32 | 1 |
| Mitochon Pharmaceuticals, Inc. | 33 | 1 |
| Phosphagenics Limited | 34 | 1 |
| Se-cure Pharmaceuticals Ltd. | 35 | 1 |
| Sinclair Pharma Plc | 36 | 1 |
| Stratatech Corporation | 37 | 1 |
| Tissue Therapies Limited | 38 | 1 |
| USV Pvt Ltd | 39 | 1 |
| Burns Therapeutics Assessment | 40 | 10 |
| Assessment by Monotherapy Products | 40 | 1 |
| Assessment by Combination Products | 41 | 1 |
| Assessment by Target | 42 | 2 |
| Assessment by Mechanism of Action | 44 | 2 |
| Assessment by Route of Administration | 46 | 2 |
| Assessment by Molecule Type | 48 | 2 |
| Drug Profiles | 50 | 35 |
| (cerium nitrate hexahydrate + silver sulfadiazine) Drug Profile | 50 | 1 |
| A-3APO Drug Profile | 51 | 1 |
| AG-110 Drug Profile | 52 | 1 |
| albumin (recombinant) Drug Profile | 53 | 1 |
| ALLO-ASC Drug Profile | 54 | 1 |
| Biochaperone PDGF-BB Drug Profile | 55 | 2 |
| Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis Drug Profile | 57 | 1 |
| bromelains Drug Profile | 58 | 3 |
| Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns Drug Profile | 61 | 2 |
| Cell Therapy for Dermatology and Immunology Drug Profile | 63 | 2 |
| epidermal growth factor biosimilar Drug Profile | 65 | 1 |
| Gene Therapy for Burns Drug Profile | 66 | 1 |
| IMSP-001 Drug Profile | 67 | 1 |
| lidocaine hydrochloride Drug Profile | 68 | 1 |
| Monoclonal Antibody Conjugate to Target TNF-alpha for Burns, Inflammation and Wounds Drug Profile | 69 | 1 |
| MP-101 Drug Profile | 70 | 1 |
| Neu-2000 Drug Profile | 71 | 2 |
| Nu-2 Drug Profile | 73 | 1 |
| Oligomer G for Wounds And Burns Drug Profile | 74 | 1 |
| P-12 Drug Profile | 75 | 1 |
| P-148 Drug Profile | 76 | 1 |
| PEP-04 Drug Profile | 77 | 1 |
| Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders Drug Profile | 78 | 1 |
| SC-106 Drug Profile | 79 | 1 |
| silver sulfadiazine Drug Profile | 80 | 1 |
| Small Molecules for Burn Drug Profile | 81 | 1 |
| sodium hypochlorite Drug Profile | 82 | 1 |
| VF-002 Drug Profile | 83 | 1 |
| XF-70 Drug Profile | 84 | 1 |
| Burns Dormant Projects | 85 | 3 |
| Burns Discontinued Products | 88 | 1 |
| Burns Product Development Milestones | 89 | 16 |
| Featured News &Press Releases | 89 | 1 |
| Jun 07, 2016: MediWound s NexoBrid Receives Reimbursement in Italy | 89 | 1 |
| May 19, 2016: MediWound s NexoBrid Highlighted in Best Oral Presentation at the British Burn Association 49th Annual Conference and Scientific Meeting | 89 | 1 |
| May 02, 2016: MediWound s NexoBrid to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting | 90 | 2 |
| Feb 29, 2016: MediWound Expands NexoBrid to India, Bangladesh and Sri Lanka Through Distribution Agreement With Learning Organized | 92 | 1 |
| Feb 03, 2016: Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS) | 92 | 1 |
| Jan 11, 2016: MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters | 93 | 1 |
| Nov 02, 2015: MediWound Provides Humanitarian Aid for a Mass Casualty Event in Romania | 94 | 1 |
| Oct 20, 2015: Argentina's Ministry of Health Approves MediWound's NexoBrid | 95 | 1 |
| Sep 30, 2015: MediWound Awarded BARDA Contract Valued Up to $112 Million for Development and Procurement of NexoBrid for the U.S. | 95 | 1 |
| Sep 29, 2015: MediWound Reports Highlights From the European Burns Association Congress | 96 | 2 |
| Sep 10, 2015: MediWound's NexoBrid Highlighted at the 16th European Burns Association Congress | 98 | 4 |
| Apr 29, 2015: Poster Presentation Highlighting NexoBrid Awarded Best-in-Category in Wound Care Practice at the American Burn Association 47th Annual Meeting | 102 | 1 |
| Apr 21, 2015: MediWound's NexoBrid Highlighted in Presentations at the 2015 American Burn Association 47th Annual Meeting | 102 | 1 |
| Apr 20, 2015: MediWound Initiates U.S. Phase 3 Trial With NexoBrid to Treat Severe Burns | 103 | 1 |
| Mar 23, 2015: MediWound's NexoBrid Highlighted in a Presentation at the International Conference on Minimally Invasive Medicine | 104 | 1 |
| Appendix | 105 | 2 |
| Methodology | 105 | 1 |
| Coverage | 105 | 1 |
| Secondary Research | 105 | 1 |
| Primary Research | 105 | 1 |
| Expert Panel Validation | 105 | 1 |
| Contact Us | 105 | 1 |
| Disclaimer | 106 | 1 |
